BERLIN, July 31, 2025 – Global law firm Greenberg Traurig, LLP has advised Gilde Healthcare on the establishment of a new international neuroimaging technology platform. In a complex cross-border transaction, Greenberg Traurig provided legal advice to the private equity investor on parallel investments in NIRx Medical Technologies (Germany/USA) and Artinis Medical Systems (Netherlands) – both recognized leaders in the field of functional near-infrared spectroscopy (fNIRS) solutions. Together, the two companies form a new global market leader in fNIRS technologies, aiming to drive innovation and the adoption of advanced neuroimaging research tools worldwide.
Gilde Healthcare is a specialized healthcare investor, managing over €2.6 billion across two fund strategies: private equity and venture/growth.
A cross-border team from Greenberg Traurig, led by Berlin Partner Henrik Armah, together with attorneys from the firm’s German, U.S., and Dutch offices, advised Gilde Healthcare throughout the two M&A transactions. The team’s work included the implementation of the holding company, the sellers’ rollovers, the international tax structure, and regulatory requirements across all three jurisdictions.
Background:
Gilde Healthcare and Greenberg Traurig have a long-standing trusted relationship. The firm’s Berlin office regularly counsels Gilde on its investments, including transactions involving medical technology manufacturers Acti-Med and EUROPIN, as well as surgical instruments manufacturers Christian Diener and Koscher & Würtz. On this particularly complex transaction, the Greenberg Traurig team leveraged its experience in multijurisdictional deals and its long-standing relationship with Gilde Healthcare to support the client.